These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30564083)

  • 1. Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice.
    Fahimi H; Sadeghizadeh M; Hassan ZM; Auerswald H; Schreiber M
    EXCLI J; 2018; 17():1054-1068. PubMed ID: 30564083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.
    Chen HW; Hu HM; Wu SH; Chiang CY; Hsiao YJ; Wu CK; Hsieh CH; Chung HH; Chong P; Leng CH; Pan CH
    PLoS One; 2015; 10(12):e0145717. PubMed ID: 26714037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico analysis of an envelope domain III-based multivalent fusion protein as a potential dengue vaccine candidate.
    Fahimi H; Sadeghizadeh M; Mohammadipour M
    Clin Exp Vaccine Res; 2016 Jan; 5(1):41-9. PubMed ID: 26866023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes.
    Khanam S; Etemad B; Khanna N; Swaminathan S
    Am J Trop Med Hyg; 2006 Feb; 74(2):266-77. PubMed ID: 16474083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.
    Mota J; Acosta M; Argotte R; Figueroa R; Méndez A; Ramos C
    Vaccine; 2005 May; 23(26):3469-76. PubMed ID: 15837370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice.
    Chiang CY; Pan CH; Chen MY; Hsieh CH; Tsai JP; Liu HH; Liu SJ; Chong P; Leng CH; Chen HW
    Sci Rep; 2016 Jul; 6():30648. PubMed ID: 27470096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice.
    Rajpoot RK; Shukla R; Arora U; Swaminathan S; Khanna N
    Sci Rep; 2018 Jun; 8(1):8643. PubMed ID: 29872153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.
    Izquierdo A; García A; Lazo L; Gil L; Marcos E; Alvarez M; Valdés I; Hermida L; Guillén G; Guzmán MG
    Arch Virol; 2014 Oct; 159(10):2597-604. PubMed ID: 24841761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
    Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.
    Etemad B; Batra G; Raut R; Dahiya S; Khanam S; Swaminathan S; Khanna N
    Am J Trop Med Hyg; 2008 Sep; 79(3):353-63. PubMed ID: 18784226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
    Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
    Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetravalent formulation of polymeric nanoparticle-based vaccine induces a potent immune response against dengue virus.
    Khan RA; Ahmed F; Afroz S; Khan N
    Biomater Sci; 2022 May; 10(11):2917-2928. PubMed ID: 35470821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
    Apt D; Raviprakash K; Brinkman A; Semyonov A; Yang S; Skinner C; Diehl L; Lyons R; Porter K; Punnonen J
    Vaccine; 2006 Jan; 24(3):335-44. PubMed ID: 16125280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection.
    Hu HM; Chen HW; Hsiao YJ; Wu SH; Chung HH; Hsieh CH; Chong P; Leng CH; Pan CH
    Hum Vaccin Immunother; 2016 Jul; 12(7):1678-89. PubMed ID: 26901482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
    Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
    Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.